Comparative target site pharmacokinetics of immediate- and modified-release formulations of cefaclor in humans

Journal of Clinical Pharmacology

Volumn 42, Issue 4, 2002, Pages 403-411

  De La Peña, Amparo ^a   Brunner, Martin ^b   Eichler, Hans Georg ^b   Rehak, Edelgard ^c   Gross, Jens ^c   Thyroff Friesinger, Ursula ^c   Müller, Markus ^a,b   Derendorf, Hartmut ^a,d  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF VIENNA   (Austria)

^c Sandoz Biopharmaceuticals   (Germany)

^d Department of Pharmaceutics ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFACLOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG STRUCTURE; HUMAN; HUMAN EXPERIMENT; INTERSTITIAL FLUID; MALE; MEAN RESIDENCE TIME; MICRODIALYSIS; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SKELETAL MUSCLE; SUSTAINED RELEASE FORMULATION; VOLUNTEER;

EID: 0036209997     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700222011454     Document Type: Article

References (27)

1. Continuous infusion of beta-lactam antibiotics
2. Antibiotic selection factors and description of a hospital-based outpatient antibiotic therapy program in the USA
3. Beta-lactam antibiotics: Is continuous infusion the preferred method of administration?
4. Pulse dosing versus continuous infusion of antibiotics: Pharmacokinetic-pharmacodynamic considerations
5. Optimal dosage regimen for penicillins: Bolus or continuous infusion?
6. Continuous infusion of beta-lactam antibiotics: A potential strategy to improve parenteral antimicrobial therapy
7. Continuous infusion of cefazolin is superior to intermittent dosing in decreasing infection after hemorrhagic shock
8. Continuous infusion of beta-lactam antibiotics
9. Killing and regrowth of bacteria in vitro: A review
10. Pharmacokinetic profile of cefaclor
11. Metabolism of (14C) cefaclor, a cephalosporin antibiotic, in three species of laboratory animals
12. AHFS Cefaclor
13. Phase I study of multiple-dose cefprozil and comparison with cefaclor
14. Comparison of cefprozil and cefaclor pharmacokinetics and tissue penetration
15. Pharmacokinetics of cefuroxime axetil and cefaclor: Relationship of concentrations in serum to MICs for common respiratory pathogens
16. Pharmacokinetics of cefaclor AF: Effects of age, antacids and H2-receptor antagonists
17. Microdialysis in clinical drug delivery studies
18. Drug distribution: The forgotten relative in clinical pharmacokinetics
19. Characterization of peripheral-compartment kinetics of antibiotics by in vivo microdialysis in humans
20. Distribution and antimicrobial activity of ciprofloxacin in human soft tissues
21. Penetration of moxifloxacin into peripheral compartments in humans
22. Target site concentrations after continuous infusion and bolus injection of cefpirome to healthy volunteers
23. Effect of temperature and mobile phase composition on RP-HPLC separation of cephalosporins
24. Evaluation of the relative efficacy of various techniques for deproteinizing plasma samples prior to high-performance liquid chromatographic analysis
25. Penetration of cefaclor into the interstitial space fluid of skeletal muscle and lung tissue in rats
26. Transport mechanisms responsible for the absorption of loracarbef, cefixime, and cefuroxime axetil into human intestinal Caco-2 cells
27. Cefaclor uptake by the proton-dependent dipeptide transport carrier of human intestinal Caco-2 cells and comparison to cephalexin uptake